| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6086be35a3fb922a66dd2d91524920ad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00 |
| filingDate |
2006-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d690c01696451493777f37ce6374168 |
| publicationDate |
2008-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20080030559-A |
| titleOfInvention |
Pharmaceutical composition containing arsenic acid, sodium salt thereof and derivatives thereof for treating genitourinary cancer and metastases thereof. |
| abstract |
The present application relates to pharmaceutical compositions and methods for the treatment of urogenital diseases and bone metastases in humans, wherein the pharmaceutical compositions contain an effective amount of arsenic alkali metal salts or arsenic alkaline earth metal salts and / or pharmaceutically acceptable adjuvants. . Alkaline arsenic acid metal salts of the present invention are sodium meta-arsenic arsenate (AsO 2 Na) or meta-potassium arsenate (AsO 2 K). The effective amount of the arsenic alkali metal salt or arsenic alkali earth metal salt is 0.0001 to 1500 mg / kg body weight / day, preferably 1 to 1000 mg / kg body weight / day, more preferably 1 to 150 mg / unit body weight. Kg / day, most preferably 50-100 mg / unit body weight kg / day. Dosage formulations of the pharmaceutical compositions of the invention are preferably oral dosage forms such as tablets, capsules, powders and / or solutions containing a pharmaceutically acceptable carrier, diluent or excipient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101309844-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022035145-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022035147-A1 |
| priorityDate |
2005-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |